Literature DB >> 11442356

Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease.

W A Pedersen1, D McCullers, C Culmsee, N J Haughey, J P Herman, M P Mattson.   

Abstract

We previously reported that mice over-expressing the human amyloid precursor protein gene with the double Swedish mutation of familial Alzheimer's disease (mtAPP), which exhibit progressive deposition of amyloid beta-peptide in hippocampal and cortical brain regions, have an impaired ability to maintain a sustained glucocorticoid response to stress. Corticotropin releasing hormone (CRH), which initiates neuroendocrine responses to stress by activating the hypothalamic-pituitary-adrenal (HPA) axis, is expressed in brain regions prone to degeneration in Alzheimer's disease. We therefore tested the hypothesis that CRH can modify neuronal vulnerability to amyloid beta-peptide toxicity. In primary neuronal culture, CRH was protective against cell death caused by an amyloid-beta peptide, an effect that was blocked by a CRH receptor antagonist and by an inhibitor of cyclic AMP-dependent protein kinase. The increased resistance of CRH-treated neurons to amyloid toxicity was associated with stabilization of cellular calcium homeostasis. Moreover, CRH protected neurons against death caused by lipid peroxidation and the excitotoxic neurotransmitter glutamate. The level of mRNA encoding CRH was unchanged in mtAPP mouse brain, whereas the levels of mRNAs encoding glucocorticoid and mineralocorticoid receptors were subtly altered. Our results suggest that disturbances in HPA axis function can occur independently of alterations in CRH mRNA levels in Alzheimer's disease brain and further suggest an additional role for CRH in protecting neurons against cell death. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442356     DOI: 10.1006/nbdi.2001.0395

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  26 in total

Review 1.  Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

2.  Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease.

Authors:  Jennifer Horgan; Jose Javier Miguel-Hidalgo; Martha Thrasher; Garth Bissette
Journal:  J Alzheimers Dis       Date:  2007-09       Impact factor: 4.472

Review 3.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

4.  Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain.

Authors:  Sarah C Hopp; Nathan A Bihlmeyer; John P Corradi; Charles Vanderburg; Angela M Cacace; Sudeshna Das; Timothy W Clark; Rebecca A Betensky; Bradley T Hyman; Eloise Hudry
Journal:  J Neurochem       Date:  2018-09-07       Impact factor: 5.372

5.  Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's Disease Progression.

Authors:  Bing Bai; Xusheng Wang; Yuxin Li; Ping-Chung Chen; Kaiwen Yu; Kaushik Kumar Dey; Jay M Yarbro; Xian Han; Brianna M Lutz; Shuquan Rao; Yun Jiao; Jeffrey M Sifford; Jonghee Han; Minghui Wang; Haiyan Tan; Timothy I Shaw; Ji-Hoon Cho; Suiping Zhou; Hong Wang; Mingming Niu; Ariana Mancieri; Kaitlynn A Messler; Xiaojun Sun; Zhiping Wu; Vishwajeeth Pagala; Anthony A High; Wenjian Bi; Hui Zhang; Hongbo Chi; Vahram Haroutunian; Bin Zhang; Thomas G Beach; Gang Yu; Junmin Peng
Journal:  Neuron       Date:  2020-01-08       Impact factor: 17.173

6.  CRF and urocortin 3 protect the heart from hypoxia/reoxygenation-induced apoptosis in zebrafish.

Authors:  Tegan A Williams; Jillian C Bergstrome; Juliana Scott; Nicholas J Bernier
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-05-24       Impact factor: 3.619

7.  Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor.

Authors:  Jeffrey S Stehouwer; Matthew S Birnbaum; Ronald J Voll; Michael J Owens; Susan J Plott; Chase H Bourke; Michael A Wassef; Clinton D Kilts; Mark M Goodman
Journal:  Bioorg Med Chem       Date:  2015-06-19       Impact factor: 3.641

8.  Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I.

Authors:  Ward A Pedersen; Ruiqian Wan; Peisu Zhang; Mark P Mattson
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

9.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

10.  Subcellular plasticity of the corticotropin-releasing factor receptor in dendrites of the mouse bed nucleus of the stria terminalis following chronic opiate exposure.

Authors:  A Jaferi; D A Lane; V M Pickel
Journal:  Neuroscience       Date:  2009-06-17       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.